Heart failure & cardiomyopathies
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy
Authors' conclusion
Tafamidis improves clinical outcomes and limits the progression of cardiac remodeling in ATTR-CM.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
- Participants
- 2,973 patients30 studies
- Comparison
- Tafamidis vs placebo
- Outcome
- All-cause mortality and CV death
Pooled result
As reported in the abstract
Tafamidis vs PlaceboOdds ratio (95% CI)
All-cause mortality
0.19(0.07–0.56)
CV death
0.08(0.02–0.30)
Further pooled results
SMD
| Outcome | Tafamidis | Placebo | P value |
|---|---|---|---|
| 6-minute walk distance | 0.04 | −0.29 | P = 0.002 |
| Serum NT-proBNP | −0.03 | 0.41 | P < 0.001 |
| Global longitudinal strain (echocardiography) | 0.06 | 0.50 | P = 0.003 |
| Heart to contralateral ratio (Tc-99m pyrophosphate scintigraphy) | −0.23 | −1.17 | P = 0.037 |
CMR parameters after tafamidis
- Better extracellular volume
- P = 0.003
- Better LVEF
- P < 0.001
- Better RV ejection fraction
- P = 0.001
- Better right atrium area
- P = 0.033
Original publication
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy. JACC Adv. Published 19 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →